Company: BIAF
Filing Date: 2025-04-15
Form Type: PRE 14A
Source: 0001641172-25-004857
Chunk: 6

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-15
Form: PRE 14A
Chunk 6
---
ation, as amended, in substantially                                                                                             
 the form attached to this Proxy Statement as Appendix A, at the discretion of our Board, to effect a reverse stock split (the                                                                                       
 “Reverse Stock Split”) with respect to the Company’s issued and outstanding shares of Common Stock,                                                                                                                 
 including stock held by the Company as treasury shares, at a ratio of 1-for-2 to 1-for-25 (the “Range”),                                                                                                            
 with the ratio within such Range (the “Reverse Stock Split Ratio”) to be determined at the discretion of                                                                                                            
 the Board and included in a public announcement, subject to the authority of the Board of Directors to abandon such amendment (the                                                                                  
 Reverse Stock Split Proposal);                                                                                                                                                                                      |
| Proposal No. 4: To consider and approve                                                                                                                                                                             
 the issuance of up to an aggregate of 2,926,166 shares of our common stock upon the exercise of our common stock purchase warrants issued in connection with our private placement offering that closed on February 
 26, 2025, that may be equal to or exceed 20% of our common stock outstanding before such offering (the Warrant Exercise Proposal).                                                                                  
 Proposal No. 5: To consider and approve                                                                                                                                                                             
 the adjournment of the Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies                                                                              
 in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal                                                                               
 and the Warrant Exercise Proposal (the “Adjournment Proposal”).                                                                                                                                                     |

Additionally, the proxies, at their discretion and
if designated as such, are authorized to vote upon such other business as may properly come before the Annual Meeting or any continuation,
postponement, or adjournment thereof.

| 2 |

Who is entitled to vote?

Stockholders as of the close of business on the record
date of April 8, 2025 (the “Record Date”), are entitled to vote at the Annual Meeting or any postponement or
adjournment thereof. As of the Record Date, there were 18,255,824 shares of Common Stock outstanding.

How many votes per share of Common Stock held are stockholders entitled to?

Stockholders have one vote per share on all matters
presented at the Annual Meeting.

What is the difference between holding shares of Common Stock as a “stockholder of record” and holding shares in “street name”?

Shares held as a “stockholder of record